NASDAQ:HRMY

Harmony Biosciences Holdings Stock News

etoro logo Buy HRMY
*Your capital is at risk
$32.10
+1.19 (+3.85%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.")
UBS initiated coverage on Harmony Biosciences Holdings Inc HRMY, a commercial-stage biopharmaceutical company focused on rare neurological disorders.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks offers
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
PLYMOUTH MEETING, Pa. , Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming inve
Harmony Biosciences' main product, WAKIX, drives significant revenue growth, with expansion potential in treating narcolepsy and other conditions, despite past controversies. The company's strategic a
Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Today, we are revisiting the biopharma name Harmony Biosciences for the first time in nearly a year and a half. The company is nicely profitable thanks to its flagship product WAKIX and Harmony has a
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investo
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.56 per
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Da
PLYMOUTH MEETING, Pa. , July 23, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2024 financial results on Tuesday, August 6,
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investo
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE